Core Viewpoint - Hongyuan Pharmaceutical's executives indicated that some of their pre-IPO restricted shares will become tradable on September 20, 2024, following the expiration of the lock-up period [2]. Summary by Relevant Sections - **Executive Shareholding**: The company stated that during the tenure of the executives, 25% of their total shareholdings will be unlocked annually, while the remaining 75% will remain locked automatically [2].

Group 1 - The core issue raised by investors pertains to the significant difference between the beginning and ending balances of the construction in progress for the Luotian hexafluorophosphate sodium project in the 2025 semi-annual report [2] - The company clarified that the decrease in the balance is primarily due to part of the project reaching the intended usable state, leading to its reclassification from construction in progress to fixed assets in accordance with the Accounting Standards for Enterprises [2]

Group 1 - The company Hongyuan Pharmaceutical (301246) has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company's market share for metronidazole raw materials is leading in the industry, with products sold to dozens of countries and regions globally [1] - The company has established good cooperative relationships with well-known pharmaceutical enterprises both domestically and internationally [1]

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products and holds a leading market share in the active pharmaceutical ingredient metronidazole, with products sold to dozens of countries and regions globally, establishing good partnerships with well-known pharmaceutical companies both domestically and internationally [1] Group 1 - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company holds a leading market share in metronidazole active pharmaceutical ingredients [1] - The company's products are sold to dozens of countries and regions globally [1] Group 2 - The company has established good partnerships with well-known pharmaceutical companies [1]

Core Viewpoint - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products and holds a leading market share in the active pharmaceutical ingredient metronidazole, with products sold to dozens of countries and regions globally, establishing strong partnerships with well-known pharmaceutical companies [1] Group 1 - The company has a designed production capacity of 8,000 tons per year for lithium hexafluorophosphate products [1] - The company holds a leading market share in metronidazole active pharmaceutical ingredients [1] - The company's products are sold to dozens of countries and regions globally [1] Group 2 - The company has established strong partnerships with well-known pharmaceutical companies [1]

Group 1 - The company, Hongyuan Pharmaceutical (301246), responded to investor inquiries on November 19, indicating that details regarding product production and planning should be monitored through the company's information disclosures [1]

Core Points - The company announced the construction project of the Wuxue Hongyuan plant, which includes public utilities and auxiliary production facilities [1] - The budget for the Wuxue Hongyuan plant supporting project is 138 million yuan, with actual investment reaching the same amount by the mid-2025 report, indicating a project progress of 99.95% [3] - The expected completion date for the project is September 18, 2025 [3] Summary by Categories - **Project Details** - The main construction content of the Wuxue Hongyuan plant supporting project includes public utilities and auxiliary production facilities [1] - **Financials** - The project has a budget of 138 million yuan, with actual expenditures matching this budget as of the mid-2025 report [3] - **Progress and Timeline** - The project is nearly complete, with a progress rate of 99.95%, and is expected to be finished by September 18, 2025 [3]

Core Viewpoint - Hongyuan Pharmaceutical provided insights into its procurement of production raw materials, emphasizing the importance of various factors in the purchasing process [1] Group 1: Raw Materials - The main raw materials required by the company include ethylene glycol, ethylene oxide, acetaldehyde, nitric acid, ammonia water, lithium fluoride, and methyl cyanoacetate [1] - Most of these materials are basic chemical products, with a large number of companies in the industry and relatively mature processes [1] Group 2: Procurement Considerations - When procuring raw materials, the company considers multiple factors such as price, quality, timeliness of supply, stability, payment terms, and transportation [1] - Detailed information regarding the procurement prices of major raw materials from 2019 to 2021 can be found in the company's prospectus, specifically in Section 6 "Business and Technology" and Chapter 5 "Purchasing Situation of the Issuer" [1]

Core Viewpoint - The company is enhancing its lithium battery segment by integrating electrolyte additives and functional lithium salts with its lithium hexafluorophosphate business, aiming to improve business scale and market competitiveness [1] Group 1 - The company is actively engaging with investors through interactive platforms to provide updates on its strategic initiatives [1] - The focus on electrolyte additives and functional lithium salts indicates a strategic move to diversify and strengthen its product offerings in the lithium battery market [1] - The integration of these products with the existing lithium hexafluorophosphate business is expected to create synergies that will benefit the overall business performance [1]

证券日报网讯宏源药业11月14日在互动平台回答投资者提问时表示，公司产品成本受多种因素影响，具 体营业收入、营业成本、营业利润情况，请关注公司定期报告。 （文章来源：证券日报） ...